Pyxis Oncology raises $152m in Series B round for cancer therapies
Pyxis Oncology, a Boston-based biotech company, has raised $152 million in a Series B financing round co-led by Arix Bioscience and RTW Investments. The company ... Read More
Aura Biosciences raises $80m for VDC therapies for cancers
Aura Biosciences, a portfolio company of UK-based Arix Bioscience, has raised $80 million in a new funding round for developing virus-like drug conjugate (VDC) therapies ... Read More